NCT05881057Not yet recruiting
Application of SERS Technology Based Intraoperative Navigation System in Lung Cancer
Application of Surface-enhanced Raman Scatting (SERS) Technology Based Intraoperative Navigation System in Lung Cancer
Source: ClinicalTrials.gov · Last updated 30 May 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study aims to explore the application of Surface-enhanced Raman Scatting (SERS) technology in lung cancer surgery and clarify its mechanism through multi-omics mass spectrometry platform, and then further prove the clinical transformation value of this technology.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 19 May 2023
- Start date
- Jun 2023
- Primary completion date
- Jun 2027
- Lead sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Diseases
- Lung cancer
- NCT number
- NCT05881057
What you commit to
- Study type: Observational
- Planned participants: 200
- From Jun 2023 to the primary completion date, Jun 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients had received previous systemic therapy for lung cancer.
Other illness
- Unresectable lung cancer patients.
- Patients with other active malignant tumors within the past year or at the same time.
- The patient had a known history of psychotropic drug abuse or drug use; She had a history of alcohol abuse.
Other
- According to the investigator's judgment, the patient had other factors that may lead to the early termination of the study.
Who the study is looking for
- Voluntary participation in clinical research; Fully understand and informed the study and sign the informed consent form (ICF); Be willing to follow and be able to complete all trial procedures.
- Male or female aged 18-75 years or more when signing ICF.
- Extended tumor resection was performed to remove the lung tumor tissue, and the resection margin was ≥2cm from the tumor margin.
- The effective measured diameter of all the lung tissues to be measured was greater than 0.5cm.
- The patient had not received previous systemic therapy for cancer.
Age in the registry: 19 years to 75 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.